Atrial fibrillation (AF) represents an important challenge in sports cardiology, with implications for diagnosis, treatment, and eligibility for competitive and recreational exercise. Regular physical activity provides substantial cardiovascular benefits and is generally associated with a lower risk of AF, whereas long-term exposure to high-volume endurance exercise has been associated with a higher AF prevalence, particularly among male master athletes. However, this relationship should not be interpreted according to a simple cause-and-effect model. Exercise-related atrial remodelling, autonomic changes, inflammation, and hemodynamic stress may contribute to arrhythmogenesis, but their clinical expression likely depends on individual clinical, structural, autonomic, and genetic susceptibility. AF in athletes therefore requires a comprehensive diagnostic evaluation aimed at characterizing the arrhythmia, identifying modifiable risk factors, and excluding underlying cardiovascular disease. Management should consider symptoms, arrhythmic burden, type of sport, performance expectations, thromboembolic and bleeding risks, and the underlying substrate. Anticoagulation should follow established thromboembolic risk assessment while considering sport-specific traumatic and bleeding risks. Rhythm control is particularly relevant in athletes, in whom long-term antiarrhythmic drug therapy may be limited by tolerability and effects on exercise performance; catheter ablation represents an important therapeutic option in appropriately selected individuals. Return-to-play decisions should consider arrhythmia control, cardiac substrate, and sport-specific demands. AF should not automatically lead to restriction from physical activity; exercise should instead be individually prescribed to preserve its cardiovascular benefits while minimizing conditions potentially promoting AF development or recurrence.